FAQ

incobotulinumtoxinA

Known as: BoNT-A 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2018
0102020052018

Related topics

Related topics

5 relations

Broader (3)

Botulinum Toxin Type ANeuromuscular AgentsNeurotoxins

Narrower (2)

NT 201Xeomin

Related mentions per year

Related mentions per year

1937-2018
19401960198020002020
incobotulinumtoxinA
Neurotoxins
Botulinum Toxin Type A
Xeomin
Neuromuscular Agents
NT 201

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Safety aspects of incobotulinumtoxinA high-dose therapy
Botulinum toxin (BT) used for dystonia and spasticity is dosed according to the number of target muscles and the severity of… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?
2013
2013
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm
IncobotulinumtoxinA (Xeomin®, NT 201) is a purified botulinum toxin type A free from accessory (complexing) proteins. Previous… (More)
  • table 2
  • table 1
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2013
2013
Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®)
Several botulinum toxin (BT) drugs are licensed for the treatment of cervical dystonia (CD). We wanted to compare the efficacy… (More)
  • figure 1
Is this relevant?
2013
2013
Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia
INTRODUCTION Previously, controlled trials have demonstrated the efficacy and tolerability of fixed doses of incobotulinumtoxinA… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2011
2011
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
OBJECTIVE IncobotulinumtoxinA differs from available formulations in that it does not have accessory proteins… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2011
2011
Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay
The biological potency of botulinum toxin (BT) drugs is determined by a standardised LD50 assay. However, the potency labelling… (More)
  • table 1
  • table 2
Is this relevant?
2011
2011
A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.
OBJECTIVE To investigate the efficacy and safety of incobotulinumtoxinA (also known as botulinum toxin type A [150 kDa], free… (More)
Is this relevant?
2011
2011
Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
IncobotulinumtoxinA (NT 201, Xeomin) is a highly purified botulinum neurotoxin type A formulation, free from complexing proteins… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2011
2011
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
Even though conventional botulinum neurotoxin (BoNT) products have shown successful treatment results in patients with benign… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines.
BACKGROUND Use of botulinum toxin for esthetic purposes has rapidly expanded over the last 20 years. IncobotulinumtoxinA, also… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?